A New Pancreatic Cancer Pill Lists at $39,800 a Month, and What Patients Actually Owe Varies Widely

A New Pancreatic Cancer Pill Lists at $39,800 a Month, and What Patients Actually Owe Varies Widely

Rasonque lists at about $477,600 a year. Here is what Medicare and commercially insured patients may actually pay for the new pancreatic cancer pill.

Has pancreatic cancer met its match? — Harvard Gazette

Frontline researcher sees a newly approved medication as a "critical first step" toward transformation of care.

As daraxonrasib hits the clinic, Frank McCormick says RAS is bigger than pancreatic cancer

Last month, FDA approved the RAS inhibitor, daraxonrasib, sponsored by Revolution Medicines Inc. and also known as Rasonque, for patients with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This episode is available on Spotify, Apple Podcasts, and Youtube. In this week’s episode […]

FDA Approves First in Class Targeted Therapy for Metastatic Pancreatic Cancer

The US FDA approved Rasonque (daraxonrasib), a RAS inhibitor for the most common form of pancreatic cancer—delivering a new treatment option to patients with advanced pancreatic cancer months ahead of schedule. [US FDA] Press Release